Natural polyphenols effects on protein aggregates in Alzheimer's and Parkinson's prion-like diseases

被引:1
|
作者
Aline Freyssin [1 ]
Guylène Page [1 ]
Bernard Fauconneau [1 ]
Agnès Rioux Bilan [1 ]
机构
[1] University of Poitiers, EA3808 NEUVACOD (Neurovascular Unit and Cognitive Disorders)
关键词
natural polyphenols; protein aggregates; Alzheimer’s disease; amyloid peptide; amyloid plaques; hyperphosphorylated tau; Parkinson’s disease; α-synuclein; synphilin-1;
D O I
暂无
中图分类号
R749.16 [];
学科分类号
100203 ;
摘要
Alzheimer’s and Parkinson’s diseases are the most common neurodegenerative diseases. They are characterized by protein aggregates and so can be considered as prion-like disease. The major components of these deposits are amyloid peptide and tau for Alzheimer’s disease, α-synuclein and synphilin-1 for Parkinson’s disease. Drugs currently proposed to treat these pathologies do not prevent neurodegenerative processes and are mainly symptomatic therapies. Molecules inducing inhibition of aggregation or disaggregation of these proteins could have beneficial effects, especially if they have other beneficial effects for these diseases. Thus, several natural polyphenols, which have antioxidative, anti-inflammatory and neuroprotective properties, have been largely studied, for their effects on protein aggregates found in these diseases, notably in vitro. In this article, we propose to review the significant papers concerning the role of polyphenols on aggregation and disaggregation of amyloid peptide, tau, α-synuclein, synphilin-1, suggesting that these compounds could be useful in the treatments in Alzheimer’s and Parkinson’s diseases.
引用
收藏
页码:955 / 961
页数:7
相关论文
共 50 条
  • [21] The propagation of prion-like protein inclusions in neurodegenerative diseases
    Goedert, Michel
    Clavaguera, Florence
    Tolnay, Markus
    TRENDS IN NEUROSCIENCES, 2010, 33 (07) : 317 - 325
  • [22] Immune-Directed Gene Therapeutic Development for Alzheimer's, Prion, and Parkinson's Diseases
    Maguire-Zeiss, Kathleen A.
    Federoff, Howard J.
    JOURNAL OF NEUROIMMUNE PHARMACOLOGY, 2009, 4 (03) : 298 - 308
  • [23] The Prion-Like Spreading of Alpha-Synuclein in Parkinson's Disease: Update on Models and Hypotheses
    Jan, Asad
    Goncalves, Nadia Pereira
    Vaegter, Christian Bjerggaard
    Jensen, Poul Henning
    Ferreira, Nelson
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (15)
  • [24] Immune-Directed Gene Therapeutic Development for Alzheimer’s, Prion, and Parkinson’s Diseases
    Kathleen A. Maguire-Zeiss
    Howard J. Federoff
    Journal of Neuroimmune Pharmacology, 2009, 4 : 298 - 308
  • [25] Potential contribution of exosomes to the prion-like propagation of lesions in Alzheimer's disease
    Vingtdeux, Valerie
    Sergeant, Nicolas
    Buee, Luc
    FRONTIERS IN PHYSIOLOGY, 2012, 3
  • [26] Does A "Prion-Like" Mechanism Contribute to the Spreading of Neuropathology in Parkinson's Disease?
    Brundin, Patrik
    PRION, 2010, 4 (03) : 108 - 108
  • [27] Invasive procedures in Parkinson's disease: Let's be aware we are dealing with prion-like proteins
    Cersosimo, Maria Graciela
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2015, 351 (1-2) : 200 - 201
  • [28] Pharmacogenomics of Alzheimer's and Parkinson's diseases
    Cacabelos, Ramon
    NEUROSCIENCE LETTERS, 2020, 726
  • [29] Crucial role of protein oligomerization in the pathogenesis of Alzheimer's and Parkinson's diseases
    Choi, Minee L.
    Gandhi, Sonia
    FEBS JOURNAL, 2018, 285 (19) : 3631 - 3644
  • [30] Visualization of prion-like transfer in Huntington's disease models
    Jansen, Anne H. P.
    Batenburg, Kevin L.
    Pecho-Vrieseling, Eline
    Reits, Eric A.
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2017, 1863 (03): : 793 - 800